XML 57 R47.htm IDEA: XBRL DOCUMENT
v3.23.1

License Agreements - Merus (Details) $ in Thousands | 1 Months Ended | 3 Months Ended |
--- | --- | --- | ---
Jan. 31, 2023 USD ($) | Jan. 31, 2022 item | Dec. 31, 2016 item | Mar. 31, 2023 USD ($) shares | Mar. 31, 2022 USD ($) | Dec. 31, 2022 USD ($)
License Agreements |  |  |  |  |  |
Unrealized gain (loss) on long term investments |  |  |  | $ (5,318) | $ (46,585) |
Merus |  |  |  |  |  |
License Agreements |  |  |  |  |  |
Common stock held from investment (in shares) | shares |  |  |  | 3,600,000 |  |
Fair market value of our long term investments |  |  |  | $ 65,300 |  | $ 54,900
Unrealized gain (loss) on long term investments |  |  |  | 10,400 | $ (19,000) |
Merus |  |  |  |  |  |
License Agreements |  |  |  |  |  |
Number of independent programs | item |  |  | 10 |  |  |
Number of additional preclinical discovery programs | item |  | 10 |  |  |  |
Number of programs under the resulting products are co-funded for development | item |  | 2 |  |  |  |
Associated future global development costs , if elected to co-develop (as a percent) |  | 35.00% |  |  |  |
Milestone payment made under license agreement | $ 2,500 |  |  | $ 5,500 |  |
Merus | UNITED STATES |  |  |  |  |  |
License Agreements |  |  |  |  |  |
Profit sharing (as a percent) |  |  |  | 50.00% |  |
Percentage of profit (losses) |  |  |  | 50.00% |  |
Merus | Minimum |  |  |  |  |  |
License Agreements |  |  |  |  |  |
Royalty payments on future global net sales (as a percent) |  |  |  | 6.00% |  |
Merus | Minimum | Non-US |  |  |  |  |  |
License Agreements |  |  |  |  |  |
Royalty payments on future global net sales (as a percent) |  |  |  | 6.00% |  |
Merus | Maximum |  |  |  |  |  |
License Agreements |  |  |  |  |  |
Royalty payments on future global net sales (as a percent) |  |  |  | 10.00% |  |
Merus | Maximum | UNITED STATES |  |  |  |  |  |
License Agreements |  |  |  |  |  |
Royalty payments on future global net sales (as a percent) |  |  |  | 4.00% |  |
Merus | Maximum | Non-US |  |  |  |  |  |
License Agreements |  |  |  |  |  |
Royalty payments on future global net sales (as a percent) |  |  |  | 10.00% |  |
Merus | Development and Regulatory Milestones | Maximum |  |  |  |  |  |
License Agreements |  |  |  |  |  |
Additional milestone payments under the license agreement |  |  |  | $ 100,000 |  |
Merus | Commercialization Milestones | Maximum |  |  |  |  |  |
License Agreements |  |  |  |  |  |
Additional milestone payments under the license agreement |  |  |  | $ 250,000 |  |

X
- Definition Represents the percentage of profits and losses shared under the collaboration agreement. + References No definition available. + Details
Name: | incy_CollaborationAgreementProfitSharingPercentage
Namespace Prefix: | incy_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Represents the additional milestone payments to be made under the license agreement. + References No definition available. + Details
Name: | incy_LicenseAgreementAdditionalMilestonePayments
Namespace Prefix: | incy_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Represents the maximum number of independent programs encompassed under the collaboration agreement. + References No definition available. + Details
Name: | incy_LicenseAgreementMaximumNumberOfIndependentPrograms
Namespace Prefix: | incy_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Represents the amount of the milestone payment made under the license agreement. + References No definition available. + Details
Name: | incy_LicenseAgreementMilestonePaymentAmountPaid
Namespace Prefix: | incy_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Represents the number of additional preclinical discovery programs. + References No definition available. + Details
Name: | incy_LicenseAgreementNumberOfAdditionalPreclinicalDiscoveryPrograms
Namespace Prefix: | incy_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Represents the number of programs in which the resulting products are co-funded for development. + References No definition available. + Details
Name: | incy_NumberOfProgramsUnderWhichResultingProductsAreCoFundedForDevelopment
Namespace Prefix: | incy_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Represents the percentage of associated future global development costs from the initiation of a Phase IIb trial provided the entity elects to co-develop any compounds and/or indications. + References No definition available. + Details
Name: | incy_PercentageFundingOnCostOnPossibleElectionOfCodevelopmentOfCompounds
Namespace Prefix: | incy_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Represents the percentage of profits (losses). + References No definition available. + Details
Name: | incy_PercentageOfProfitsLosses
Namespace Prefix: | incy_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Represents range of tiered, double-digit royalty payments on future global sales if product is successfully commercialized. + References No definition available. + Details
Name: | incy_PercentageOfRoyaltyRatePayments
Namespace Prefix: | incy_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount of unrealized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI). + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 944 -SubTopic 220 -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(3)(d)) -URI https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263 Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 321 -SubTopic 10 -Section 50 -Paragraph 4 -URI https://asc.fasb.org/extlink&oid=126980263&loc=SL75117546-209714 + Details
Name: | us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Balance held at close of period in number of shares. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 946 -SubTopic 210 -Section 50 -Paragraph 6 -Subparagraph (c) -URI https://asc.fasb.org/extlink&oid=99383244&loc=d3e12121-115841 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 946 -SubTopic 320 -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-12B(Column B)) -URI https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010 + Details
Name: | us-gaap_InvestmentOwnedBalanceShares
Namespace Prefix: | us-gaap_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | instant

X
- Definition Fair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 820 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258 + Details
Name: | us-gaap_InvestmentsFairValueDisclosure
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_RelatedPartyTransactionLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=incy_MerusNVMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=incy_MerusNVMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementGeographicalAxis=country_US
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MinimumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementGeographicalAxis=us-gaap_NonUsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MaximumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | incy_AchievementOfMilestoneAxis=incy_DevelopmentAndRegulatoryMilestonesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | incy_AchievementOfMilestoneAxis=incy_CommercializationMilestonesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |